REG - Poolbeg Pharma PLC - Former Amryt Pharma Leadership Team join Poolbeg

Poolbeg PharmaAnnouncement

09/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231109:nRSI8674Sa&default-theme=true

RNS Number : 8674S  Poolbeg Pharma PLC  09 November 2023

Poolbeg Pharma plc

 

Key Senior Members of Former Amryt Pharma Leadership Team join Poolbeg Pharma

Poolbeg team boosted by highly experienced executives with track record of
success

 

9 November 2023 - Poolbeg Pharma (http://www.poolbegpharma.com/)  (AIM:
POLB, OTCQB: POLBF, 'Poolbeg' or the 'Company'), a clinical-stage
biopharmaceutical company targeting diseases with a high unmet medical need,
announces the appointment of key former executives of Amryt Pharma plc
('Amryt') to its leadership team.

 

These experienced professionals will assume pivotal roles within Poolbeg,
further enhancing the Company's expertise and capabilities. Poolbeg's
Chairman, Cathal Friel, co-founded both Poolbeg and Amryt Pharma plc. Poolbeg
intends to follow a similar strategic approach to Amryt which focusses upon
developing a number of exciting clinical assets and the acquisition of
approved and marketed drugs, which not only generate revenue but also fund the
development of a robust pipeline of innovative products.

David Allmond will join Poolbeg Pharma as Chief Business Officer from 1
December 2023. David was previously Chief Business Officer at Amryt and was
instrumental in putting in place the global commercial infrastructure at Amryt
which supported its revenue growth from c. $1.5 million when he joined in
2016, to approaching US$250 million some six years later, when Amryt was sold
to Chiesi Farmaceutici S.P.A. David played a pivotal role in Amryt, acquiring
the Lojuxta distribution rights for Europe and the Middle East in 2016 and
joined Amyrt thereafter. Lojuxta became Amryt's first approved, revenue
generating product. David also played a very significant role in Amryt's
acquisition of Aegerion in 2019 and Chiasma Pharmaceuticals in 2021.
Previously, he played a key role leading the EMEA team at Aegerion
Pharmaceuticals and was the Corporate Vice President of Global Marketing at
Celgene during a period of very rapid growth for the company having previously
established Celgene's UK operating company and led their marketing and market
access team for EMEA.

John McEvoy will become SVP, Chief Legal Officer, at Poolbeg from 1 January
2024. John was Global General Counsel at Amryt from 2017 and continued in his
role at Amryt following its sale to Chiesi Farmaceutici S.P.A. earlier this
year. John played an instrumental role in Amryt's rapid growth, leading the
acquisition of Aegerion Pharmaceuticals in 2019 and Chiasma Pharmaceuticals in
2021. He also led the company's dual-listing on Nasdaq in 2020 and its
subsequent sale to Chiesi. John is a qualified lawyer in the US (New York),
England & Wales, and Ireland.

Laura Maher will join the Company as Vice President of Clinical Operations
from 8 January 2024. Laura joined Amryt in 2018 and as Associate Director of
Clinical Operations she led the clinical research programmes for multiple
products in Amryt's pipeline including Filsuvez®, the world's first approved
epidermolysis bullosa treatment. Laura has an extensive background in Clinical
Operations having previous roles in Prothena Biosciences, Cancer Trials
Ireland, and the European Organisation for Research and Treatment of Cancer.

Cathal Friel, Co-Founder and Chairman of Poolbeg Pharma, said, "I believe that
Poolbeg has the potential to deliver the same success as Amryt, which I
co-founded in 2015 and IPO'd on AIM in 2016 and which went on to dual list on
Nasdaq in 2020 before its sale in 2023 to Chiesi Farmaceutici S.P.A. for
US$1.48 billion. When we established Poolbeg Pharma we always had the ambition
of creating a substantial biopharmaceutical company and over the last two and
a half years we have made great progress in building an innovative and
attractive pipeline.

"We welcome these exceptional individuals to the Poolbeg team as we look to
accelerate this strategy, which is focussed upon developing a number of very
exciting clinical assets and the acquisition of approved and marketed drugs,
which not only generate revenue but also fund the development of a robust
pipeline of innovative products. Their extensive experience and achievements
at Amryt Pharma align with our vision of rapidly generating revenues and
creating value for shareholders. We look forward to some very exciting months
and years ahead for the entire Poolbeg team, its stakeholders and
shareholders."

Investor presentation

Jeremy Skillington, Chief Executive Officer, Cathal Friel, Chairman, will
provide a live presentation, joined by David Allmond, incoming Chief Business
Officer, via the Investor Meet Company platform on Friday 10 November 2023
at 12.30pm GMT.

The presentation is open to analysts and investors, those who already follow
Poolbeg on the Investor Meet Company platform will automatically be invited.

 

Investors can sign up to Investor Meet for free and add Poolbeg Pharma
plc to their company dashboard via:

https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor
(https://www.investormeetcompany.com/poolbeg-pharma-plc/register-investor)

 

Enquiries

 Poolbeg Pharma Plc                                                    +44 (0) 207 183 1499

 Jeremy Skillington, CEO

 Ian O'Connell, CFO

 Cavendish Capital Markets Ltd (Nominated Adviser & Joint Broker)      +44 (0) 207 220 0500

 Geoff Nash, Charlie Beeson, Nigel Birks, Harriet Ward (ECM)

 Singer Capital Markets (Joint Broker)                                  +44 (0) 207 496 3000

 Phil Davies, Sam Butcher

 J&E Davy (Joint Broker)                                               +353 (0) 1 679 6363

 Anthony Farrell, Niall Gilchrist

 Optimum Strategic Communications                                      +44 (0) 208 078 4357

 Nick Bastin, Hana Malik, Vici Rabbetts                                poolbeg@optimumcomms.com (mailto:poolbeg@optimumcomms.com)

 

About Poolbeg Pharma

Poolbeg Pharma specialises in the development of innovative medicines to
address the unmet need in infectious and other prevalent diseases. Poolbeg
Pharma has a disciplined portfolio approach to mitigate risk, accelerate drug
development, and enhance investor returns. The Company simultaneously advances
multiple programmes in cost-effective clinical trials, rapidly generating
early human safety and efficacy data to enable early partnering /
out-licensing, with the funds generated reinvested in the pipeline. Poolbeg
Pharma also uses AI to interrogate human challenge trial data sets to quickly
identify new targets and drugs, leading to faster development and greater
commercial appeal.

 

The Company is targeting the growing infectious disease market. In the wake of
the COVID-19 pandemic, infectious disease has become one of the fastest
growing pharma markets and is expected to exceed $250bn by 2025. Through
opportunistic identification of assets which complement Poolbeg Pharma's
existing pipeline, the Company is progressing programmes in oncology and
metabolic syndromes; adding disease areas with significant addressable
markets.

 

With its initial assets from hVIVO plc (http://www.hvivo.com/) , an industry
leading infectious disease and human challenge trials business, Poolbeg Pharma
has access to knowledge, experience, and clinical data from over 20 years of
human challenge trials. The Company is using these insights to acquire new
assets as well as reposition clinical stage products, reducing spend and risk.
Amongst its portfolio of exciting assets, Poolbeg Pharma has a small molecule
immunomodulator for severe influenza and other acute inflammatory
conditions (POLB 001) which produces a highly significant reduction in p38
MAP kinase driven cytokines in a clinical setting; a first-in-class,
intranasally administered RNA-based immunotherapy for respiratory virus
infections (POLB 002); and a vaccine candidate for Melioidosis (POLB 003). The
Company is progressing two Artificial Intelligence (AI) Programmes to add
promising new assets to its pipeline as well as developing an Oral Vaccine
Programme and utilising its licensed Oral Delivery Platform to target
metabolic conditions.

 

For more information, please go to www.poolbegpharma.com
(http://www.poolbegpharma.com/)  or follow us on Twitter
(https://twitter.com/PoolbegPharma)  and LinkedIn
(https://www.linkedin.com/company/poolbeg-pharma/)  @PoolbegPharma.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZMGMFRRGFZZ